Literature DB >> 19318828

Antithrombosis Trials: Should we test therapeutic heparin adjusted based on activated partial thromboplastin time in septic shock?

Amisha V Barochia, Yan Li, Xizhong Cui, Daniel A Sweeney, Charles Natanson, Peter Q Eichacker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19318828      PMCID： PMC3383779          DOI： 10.1097/CCM.0b013e31819d2bb4

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  16 in total

1.  Low-dose heparin for severe sepsis.

Authors:  Bruce L Davidson; William H Geerts; Anthonie W A Lensing
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

2.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

3.  Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study.

Authors:  F Baudo; T M Caimi; F de Cataldo; A Ravizza; S Arlati; G Casella; D Carugo; G Palareti; C Legnani; L Ridolfi; R Rossi; A D'Angelo; L Crippa; D Giudici; G Gallioli; A Wolfler; G Calori
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

4.  Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.

Authors:  B L Warren; A Eid; P Singer; S S Pillay; P Carl; I Novak; P Chalupa; A Atherstone; I Pénzes; A Kübler; S Knaub; H O Keinecke; H Heinrichs; F Schindel; M Juers; R C Bone; S M Opal
Journal:  JAMA       Date:  2001-10-17       Impact factor: 56.272

5.  Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.

Authors:  E Abraham; K Reinhart; P Svoboda; A Seibert; D Olthoff; A Dal Nogare; R Postier; G Hempelmann; T Butler; E Martin; C Zwingelstein; S Percell; V Shu; A Leighton; A A Creasey
Journal:  Crit Care Med       Date:  2001-11       Impact factor: 7.598

6.  Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis.

Authors:  G R Bernard; E W Ely; T J Wright; J Fraiz; J E Stasek; J A Russell; I Mayers; B A Rosenfeld; P E Morris; S B Yan; J D Helterbrand
Journal:  Crit Care Med       Date:  2001-11       Impact factor: 7.598

7.  Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.

Authors:  B Eisele; M Lamy; L G Thijs; H O Keinecke; H P Schuster; F R Matthias; F Fourrier; H Heinrichs; U Delvos
Journal:  Intensive Care Med       Date:  1998-07       Impact factor: 17.440

8.  Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation.

Authors:  F Fourrier; C Chopin; J J Huart; I Runge; C Caron; J Goudemand
Journal:  Chest       Date:  1993-09       Impact factor: 9.410

9.  Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.

Authors:  Edward Abraham; Konrad Reinhart; Steven Opal; Ignace Demeyer; Christopher Doig; Angel López Rodriguez; Richard Beale; Petr Svoboda; Pierre Francois Laterre; Stuart Simon; Bruce Light; Herbert Spapen; Judy Stone; Allan Seibert; Claus Peckelsen; Cathy De Deyne; Russell Postier; Ville Pettilä; Charles L Sprung; Antonio Artigas; Sandra R Percell; Vincent Shu; Christian Zwingelstein; Jeffrey Tobias; Lona Poole; James C Stolzenbach; Abla A Creasey
Journal:  JAMA       Date:  2003-07-09       Impact factor: 56.272

10.  Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction.

Authors:  D Inthorn; J N Hoffmann; W H Hartl; D Mühlbayer; M Jochum
Journal:  Shock       Date:  1997-11       Impact factor: 3.454
View more
  1 in total

Review 1.  The effect of heparin administration in animal models of sepsis: a prospective study in Escherichia coli-challenged mice and a systematic review and metaregression analysis of published studies.

Authors:  Yan Li; Jun-Feng Sun; Xizhong Cui; Haresh Mani; Robert L Danner; Xuemei Li; Jun-Wu Su; Yvonne Fitz; Peter Q Eichacker
Journal:  Crit Care Med       Date:  2011-05       Impact factor: 7.598
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.